Login to Your Account



Other News To Note


Wednesday, July 18, 2012
• BioTime Inc., of Alameda, Calif., signed an exclusive sublicense agreement and a supply agreement with Jade Therapeutics LLC, of Park City, Utah, to provide clinical-grade HyStem hydrogels and other technology for use by Jade in developing pharmaceutical products for ophthalmologic use. Jade plans to use the hydrogels for time-release topical delivery of recombinant human growth hormone to help heal lesions on the ocular surface.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription